Multiple Myeloma | Specialty

The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.

Dr Raza on Talquetamab Plus Teclistamab in R/R Myeloma and Extramedullary Disease

August 15th 2025

Shahzad Raza, MD, discusses talquetamab in plus teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

Novel Lipo-MIT–Based Triplet Drives Responses in R/R Myeloma

August 15th 2025

Bortezomib plus mitoxantrone hydrochloride liposome and dexamethasone produced responses with manageable safety in relapsed/refractory myeloma

BCMA-Targeted Therapy Sequencing: Where Will Belantamab Fit in the Current R/R MM Treatment Landscape?

August 14th 2025

s discuss how belantamab mafodotin should be sequenced with chimeric antigen receptor (CAR) T-cell therapy, noting that prior B-cell maturation antigen (BCMA)-directed therapies can reduce CAR T efficacy and recommending CAR T first when patients are candidates.

What’s Next in CAR T? Emerging Therapies Potentially Reshaping R/R MM

August 14th 2025

Panelists discuss how emerging chimeric antigen receptor (CAR) T-cell therapies such as anito-cel show promise with potentially reduced neurologic toxicity while maintaining efficacy, and dual-targeting approaches such as CD19-B-cell maturation antigen (BCMA) constructs may provide better long-term remissions by targeting potential myeloma stem cell populations.

Daratumumab Delays Clinical Progression, Provides Proof-of-Concept for Early Intervention in MRD-Relapsed Multiple Myeloma

August 12th 2025

Krzysztof Jamroziak, MD, PhD, discusses the feasibility of MRD-guided, early intervention with daratumumab in patients with multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 8/3

August 10th 2025

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

SAR446523 Receives FDA Orphan Drug Designation for R/R Myeloma

August 9th 2025

The FDA granted orphan drug designation to SAR446523 for relapsed/refractory multiple myeloma.

Coordinating Post CAR T Care in MM: Bridging Academic and Community Practice

August 7th 2025

Panelists discuss how post-chimeric antigen receptor (CAR) T follow-up care involves coordinated joint visits between academic centers and community oncologists for the first 3 months, with ongoing education about delayed toxicities such as cranial nerve palsies, parkinsonism, and immune effector cell enterocolitis

Early Referral and Patient Education: Setting the Stage for CAR T in MM

August 7th 2025

Panelists discuss how early referral for chimeric antigen receptor (CAR) T-cell therapy is crucial for accessing clinical trials and achieving optimal outcomes, with comprehensive patient education covering unique adverse effects such as cytokine release syndrome (CRS), neurologic toxicities, and secondary malignancies balanced against extraordinary efficacy data.

Questions Arise As CAR T-Cell Therapy and Bispecific Antibody Use Increase in Relapsed/Refractory Myeloma

August 6th 2025

Prerna Mewawalla, MD, highlights sequencing strategies with CAR T-cell therapy and bispecific antibodies in managing relapsed/refractory multiple myeloma.

FDA Approves Tocilizumab Biosimilar for CAR T-Cell Therapy–Induced CRS

August 6th 2025

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology

August 6th 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Dr Popat on JNJ-5322 in Relapsed/Refractory Multiple Myeloma

August 5th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, discusses data with the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Dr Dorritie on the Role of Quadruplet Regimens in Multiple Myeloma

August 5th 2025

Kathleen A. Dorritie, MD, discusses the role of quadruplet regimens for the treatment of patients with multiple myeloma.

OncLive’s July Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

August 1st 2025

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

Dr Jamroziak on Daratumumab vs Observation in Multiple Myeloma With MRD Reappearance

July 31st 2025

Krzysztof Jamroziak, PhD, discusses findings from the phase 2 PREDATOR-MRD trial (NCT03697655).

Expert Insights: Long-Term Efficacy of Cilta-cel from CARTITUDE-1

July 31st 2025

Panelists discuss how the 5-year follow-up data from CARTITUDE-1 shows 33% of patients remain alive and progression-free at 5 years with sustained minimal residual disease (MRD) negativity, suggesting the potential for functional cure in multiple myeloma, with lower disease burden at infusion being a key predictor of long-term remission

Breaking Down CARTITUDE-4: Survival in High-Risk Patients, Extramedullary Disease, and Prior 1 to 3 Lines of Therapy

July 31st 2025

Panelists discuss how the CARTITUDE-4 subgroup analysis demonstrated that cilta-cel provides significant progression-free and overall survival advantages over standard of care across all patient subgroups, including those with high-risk cytogenetics, extramedullary disease, and varying numbers of prior therapy lines.

Trispecific Antibodies, Novel CAR T-Cell Therapies Signal Progress in R/R Myeloma

July 30th 2025

Joshua Richter, MD, outlines how trispecific antibodies and novel CAR T-cell therapies are shaping the 2025 myeloma landscape and improving patient access.

Five Under 5: Top Oncology Videos for the Week of 7/20

July 27th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.